Blog

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

Khalis Mustafayev/LinkedIn

Dec 1, 2024, 08:51

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

KhalisMustafayev, Research Scientist at Miami Cancer Institute, shared on X:

“Are BCR::ABL1 TKIs safe for cancer patients with chronic Hepatitis C? Our latest study explores the virologic effect and hepatotoxicity of BCR::ABL1 TKIs.”

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study – ScienceDirect

Authors: Khalis Mustafayev, Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa C. Ghayas, Ravin Ratan, Naveen Pemmaraju, Harrys A. Torres

cancer Courtney D. DiNardo Eduardo Yepez Guevara Elias Jabbour Harrys A. Torres hepatitis C Issa C. Ghayas Khalis Mustafayev Naveen Pemmaraju OncoDaily Oncology Ravin Ratan

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer